Gifford Shaun M, Kalra Manju, Gloviczki Peter, Duncan Audra A, Oderich Gustavo S, Fleming Mark D, Harmsen Scott, Bower Thomas C
Division of Vascular and Endovascular Surgery, Mayo Clinic, Rochester, Minn.
Division of Vascular and Endovascular Surgery, Mayo Clinic, Rochester, Minn.
J Vasc Surg Venous Lymphat Disord. 2014 Oct;2(4):397-402. doi: 10.1016/j.jvsv.2014.04.004. Epub 2014 May 24.
Intervention on the great saphenous vein (GSV) has traditionally been limited to the above-knee (AK-GSV) segment for fear of saphenous neuralgia in spite of incompetence demonstrated in the below-knee (BK-GSV) segment. Residual symptoms and need for reintervention are reported to result in nearly half the patients if the refluxing BK-GSV is ignored. Experience with endovenous ablation of the BK-GSV at the time of AK-GSV treatment is sparsely reported in the literature. The aim of this study was to evaluate the safety of endovenous ablation of the refluxing BK-GSV.
Data from consecutive patients treated with superficial venous ablation during a 48-month period from January 2010 to December 2013 were retrospectively reviewed. Demographic and procedure-related outcome and complication data were analyzed specifically for patients undergoing BK-GSV interventions.
A total of 550 patients were treated with superficial venous ablation during the study period. Of those, 61 (79 limbs) underwent BK-GSV ablation for reflux at this site. There were 36 women and 25 men (mean age, 55 years). Median Clinical, Etiologic, Anatomic, and Pathologic (CEAP) score was 3.4; 43 limbs were treated for symptomatic varicose veins (C 1-3) and 36 for advanced venous insufficiency (C 4-6); 14 limbs (18%) were treated for recurrent symptomatic varicose veins or venous insufficiency after prior superficial venous intervention with AK-GSV ablation, sclerotherapy, or stripping. Comorbidities included obesity (54%) with mean body mass index of 30.7 (range, 19 to 52), obstructive sleep apnea (10%), pulmonary hypertension (3%), and congestive heart failure (3%). Ablation was performed in 77 limbs (99%) with the VenaCure EVLT laser vein treatment (AngioDynamics, Queensbury, NY) and in two limbs by radiofrequency ablation with ClosureFAST system (VNUS Medical Technologies, San Jose, Calif). The mean length of GSV ablated was 51.2 cm (range, 26-67 cm). Endovenous ablation was performed concomitantly on 22 accessory GSVs (28%) and 10 incompetent perforators (13%). Ambulatory stab phlebectomy of branch varicosities was performed simultaneously in 59 limbs (75%). All veins treated were evaluated with ultrasound on postprocedure day 1, and no evidence of endovenous heat-induced thrombosis was detected. Eight patients (10%) went on to have preplanned sclerotherapy treatment for small-branch varicosities. Postoperative paresthesia occurred in three patients (4%) and resolved within 4 weeks. Wound infection in three (4%) stab phlebectomy wounds resolved with oral antibiotic therapy. Follow-up surveillance ultrasound was available in 32 of 79 limbs that were >6 months from the procedure. Partial late recanalization was noted in four of 32 limbs, but no patient had recurrent symptoms requiring repeated endovenous ablation during this period.
Endovenous ablation of the refluxing BK-GSV segment can be performed safely with minimal complications. Consideration should be given to concomitant ablation of the BK-GSV in treatment of patients with varicose veins with reflux extending to the BK segment of the GSV to improve long-term outcomes.
尽管膝下大隐静脉(BK-GSV)段存在功能不全,但传统上对大隐静脉(GSV)的干预仅限于膝上(AK-GSV)段,原因是担心出现隐神经痛。据报道,如果忽略反流的BK-GSV,近一半的患者会出现残留症状并需要再次干预。文献中关于在AK-GSV治疗时对BK-GSV进行腔内消融的经验报道较少。本研究的目的是评估对反流的BK-GSV进行腔内消融的安全性。
回顾性分析2010年1月至2013年12月连续48个月接受浅静脉消融治疗的患者数据。专门分析了接受BK-GSV干预患者的人口统计学、与手术相关的结局和并发症数据。
在研究期间,共有550例患者接受了浅静脉消融治疗。其中,61例(79条肢体)因该部位反流接受了BK-GSV消融。有36名女性和25名男性(平均年龄55岁)。临床、病因、解剖和病理(CEAP)评分中位数为3.4;43条肢体因有症状的静脉曲张(C 1-3)接受治疗,36条肢体因严重静脉功能不全(C 4-6)接受治疗;14条肢体(18%)在先前接受AK-GSV消融、硬化治疗或剥脱术等浅静脉干预后,因复发性有症状的静脉曲张或静脉功能不全接受治疗。合并症包括肥胖(54%),平均体重指数为30.7(范围19至52)、阻塞性睡眠呼吸暂停(10%)、肺动脉高压(3%)和充血性心力衰竭(3%)。77条肢体(99%)采用VenaCure EVLT激光静脉治疗(AngioDynamics,纽约昆斯伯里)进行消融,2条肢体采用ClosureFAST系统(VNUS Medical Technologies,加利福尼亚州圣何塞)进行射频消融。消融GSV的平均长度为51.2 cm(范围26 - 67 cm)。同时对22条副GSV(28%)和10条功能不全的穿通静脉(13%)进行了腔内消融。59条肢体(75%)同时进行了曲张静脉分支的门诊小切口静脉切除术。术后第1天对所有治疗的静脉进行超声评估,未发现腔内热诱导血栓形成的证据。8例患者(10%)继续接受了针对小分支静脉曲张的预先计划的硬化治疗。3例患者(4%)出现术后感觉异常,4周内缓解。3例(4%)小切口静脉切除术伤口发生感染,经口服抗生素治疗后痊愈。79条肢体中有32条在手术后6个月以上进行了随访超声检查。32条肢体中有4条出现部分晚期再通,但在此期间没有患者出现需要再次进行腔内消融的复发性症状。
对反流的BK-GSV段进行腔内消融可安全进行,并发症极少。对于大隐静脉反流延伸至BK段的静脉曲张患者,治疗时应考虑同时消融BK-GSV,以改善长期疗效。